Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.
--------
Question: Today, the Eiffel Tower, which serves an important role in television and radio broadcasts, is considered an architectural wonder. It attracts more visitors than any other paid tourist attraction in the world. The Eiffel Tower was designed by the French engineer and bridge builder Alexandre Gustave Eiffel for the Paris Exposition of 1889. The tower is 300 m high and consists of an open iron framework making it the highest manmade structure in the world at the time. It was almost not built. After being awarded the contract to build the tower, Eiffel discovered that the Exposition Committee would only provide about a quarter of the money needed to construct it. Eiffel himself would have to finance the balance. He thought of a deal that would make him a very rich man. He agreed to independently find the people to fund his tower but he wanted to be the only one to control of the tower and he wanted the profits for twenty years. They agreed. To everyone's surprise, including Eiffel, the tower was paid off in the first year. The deal that Eiffel came up with was probably what saved the tower from destruction. A Committee of Three Hundred was formed and they demanded an end to its building. Many members of the committee said, "They have only put up the framework of this monument, It has no skin." Many sculptors and architects protested , in the name of threatened French art and history, about the useless Eiffel Tower, in the heart of their capital. It is built of iron, which is an inferior material, and a single beam of it is unable to support large stresses. That is why the tower appears over-engineered by today's standards. Though, from this very weakness, its simple beauty can be found. If you look at the tower, the structure of it sort of copies the biological cellular structure of a plant.

Answer: What was the Eiffel Tower originally designed for?


Question: Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole derivative, is a new antituberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro and in vivo activity against drug-resistant strains of Mycobacterium tuberculosis. In this randomized, placebo-controlled, multinational clinical trial, we assigned 481 patients (nearly all of whom were negative for the human immunodeficiency virus) with pulmonary multidrug-resistant tuberculosis to receive delamanid, at a dose of 100 mg twice daily (161 patients) or 200 mg twice daily (160 patients), or placebo (160 patients) for 2 months in combination with a background drug regimen developed according to World Health Organization guidelines. Sputum cultures were assessed weekly with the use of both liquid broth and solid medium; sputum-culture conversion was defined as a series of five or more consecutive cultures that were negative for growth of M. tuberculosis. The primary efficacy end point was the proportion of patients with sputum-culture conversion in liquid broth medium at 2 months. Among patients who received a background drug regimen plus 100 mg of delamanid twice daily, 45.4% had sputum-culture conversion in liquid broth at 2 months, as compared with 29.6% of patients who received a background drug regimen plus placebo (P=0.008). Likewise, as compared with the placebo group, the group that received the background drug regimen plus 200 mg of delamanid twice daily had a higher proportion of patients with sputum-culture conversion (41.9%, P=0.04). The findings were similar with assessment of sputum-culture conversion in solid medium. Most adverse events were mild to moderate in severity and were evenly distributed across groups. Although no clinical events due to QT prolongation on electrocardiography were observed, QT prolongation was reported significantly more frequently in the groups that received delamanid. Delamanid was associated with an increase in sputum-culture conversion at 2 months among patients with multidrug-resistant tuberculosis. This finding suggests that delamanid could enhance treatment options for multidrug-resistant tuberculosis. (Funded by Otsuka Pharmaceutical Development and Commercialization; ClinicalTrials.gov number, NCT00685360.).

Answer: Which disease can be treated with Delamanid?


Question: Greenwich is on the River, five miles from the middle of London, and its history is two thousand years old. The first English people were fishermen there, and they named the place Greenwich, meaning "green village". Later the English kings and queens lived at Greenwich in their beautiful places. The name of the earliest palace was Placentia. Henry VIII lived there. He knew that England must be strong at sea. So he started two big ship-yards at Greenwich. But trouble was coming to Greenwich. In 1649, a war started in England and for eleven years there was no king. The men who had worked for him at Placentia decided to live the place themselves. They sold all its beautiful things. Finally, the war ended and King Charles II came back. But Placentia was falling down. So King Charles built a new and bigger palace, which is now open to the public. At this time, Charles was worried about losing so many of its ships at sea: their sailors did not know how to tell exactly where they were. So in 1675, Charles made John Flamsteed, the first astronomer in England, try to find the answer. Flamsteed worked in a new building on the high ground in Greenwich Park. From it with a telescope which he made himself, Flamsteed could look all round the sky. And he did, night after night, for twenty years. Carrying on Flamsteed's work a hundred years later, an astronomer called Harrison finally made a clock which told the time at sea, and helped sailors to know where they were. You can see Harrison's clock, still working, in Greenwich's museum of the sea. Because of Flamsteed's work, every country in the world now tells its time by Greenwich Time.

Answer:
Who made the first clock which could tell the time at sea?